Welcome to our dedicated page for Beigene news (Ticker: BGNE), a resource for investors and traders seeking the latest updates and insights on Beigene stock.
News about BeiGene, Ltd. (BGNE) centers on its role as a global oncology company advancing cancer medicines such as TEVIMBRA (tislelizumab) and BRUKINSA (zanubrutinib), along with a broad pipeline of solid tumor and hematology assets. The company’s announcements frequently cover regulatory milestones, clinical trial readouts, licensing deals and strategic updates tied to its oncology focus.
Recent news highlights include positive regulatory developments for TEVIMBRA, such as a positive opinion from the Committee for Medicinal Products for Human Use for first-line treatment of extensive-stage small cell lung cancer in combination with chemotherapy, European Commission approvals in first-line esophageal squamous cell carcinoma and gastric or gastroesophageal junction adenocarcinoma, and U.S. Food and Drug Administration approval for first-line treatment of certain HER2-negative gastric and gastroesophageal junction cancers. These stories typically detail Phase 3 trial results, overall survival outcomes and safety profiles.
BeiGene’s news flow also features updates from major scientific meetings, including new data from the SEQUOIA study of BRUKINSA in chronic lymphocytic leukemia/small lymphocytic lymphoma, early-phase results for sonrotoclax and BGB‑16673 in B‑cell malignancies, and broader pipeline presentations at forums such as the American Society of Hematology Annual Meeting. Additional items include a global licensing agreement for the MAT2A inhibitor SYH2039 for MTAP-deleted solid tumors and partnerships like the Test Before Treat campaign with CLL Society to promote biomarker testing in CLL/SLL.
Investors and followers of BGNE can use this news page to track regulatory decisions, clinical data releases, business development agreements, investor conference appearances and corporate identity plans, including BeiGene’s stated intent to change its name to BeOne Medicines Ltd. and its Nasdaq ticker symbol to ONC.
BeiGene, a global oncology company, announced its participation in the Goldman Sachs 45th Annual Global Healthcare Conference on June 11, 2024. The event will feature a fireside chat at 1:20 pm EDT, accessible via live webcast through BeiGene's investor relations websites. The replay will be available for 180 days post-event.
BeiGene announced new analyses for BRUKINSA® (zanubrutinib) at the ASCO Annual Meeting 2024. The data underline BRUKINSA's efficacy and safety in treating chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) compared to other BTK inhibitors (BTKis).
A network meta-analysis highlighted BRUKINSA's superior progression-free survival (PFS) over acalabrutinib in high-risk relapsed/refractory CLL patients. Additional findings indicated a trend towards better overall survival (OS) and overall response (ORR) rates.
A retrospective analysis from Kaiser Permanente revealed that BRUKINSA is well-tolerated, with lower treatment-limiting adverse events, particularly cardiac-related, compared to ibrutinib. A post-hoc analysis of the ALPINE trial showed patients on BRUKINSA had less frequent initiation of new antihypertensive medications.
Overall, BRUKINSA demonstrates a favorable clinical profile, offering significant insights for oncologists in treatment decision-making for CLL and SLL patients.
BeiGene announced it will present new data from its hematology portfolio at the European Hematology Association 2024 Hybrid Congress (EHA2024) in Madrid, Spain, June 13-16, 2024.
Highlights include 28 abstracts, with four oral presentations. Key studies focus on BRUKINSA® (zanubrutinib), sonrotoclax, and BGB-16673. BRUKINSA, in combination with venetoclax, showed strong efficacy and favorable safety in high-risk CLL/SLL patients.
Sonrotoclax demonstrated promising safety and efficacy as a monotherapy and in combination therapies, particularly with BRUKINSA. Also, BGB-16673, a BTK degrader, showed encouraging results in BTK inhibitor-resistant diseases.
These findings underscore BeiGene's commitment to advancing treatment options for B-cell malignancies and other hematological conditions.
BeiGene reported total revenues of $752 million in the first quarter of 2024, with product revenue reaching $747 million, an 82% increase from the prior-year period. BRUKINSA revenue was $489 million, showcasing growth in the U.S. and Europe. The company is focusing on advancing its late-stage hematology pipeline, improving operating leverage, and aiming for sustainable profitability. Key updates include the FDA approval for BRUKINSA in follicular lymphoma and the sales growth of TEVIMBRA in various indications. The company also highlighted progress in its hematology and solid tumor programs, along with key pipeline advancements in lung, breast, and gastrointestinal cancers.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.